Fda Be Nimble, Fda Be Quick

Congress is finally moving to reform the Food & Drug Administration--cautiously. Senator Nancy L. Kassebaum (R-Kan.) is circulating a bill that would speed up FDA reviews of drugs and medical devices. One proposed change: allowing product approvals after one major clinical trial, instead of the current two. GOP hard-liners and some industry execs favor more radical deregulation. But companies are pleased that even modest FDA reform is under way at last.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.